EMEA (Europe, Middle East and Africa) Live Attenuated Vaccine Market Report 2017

December 2017 | 106 pages | ID: EECBC518572EN
QYResearch

Abstracts

In this report, the EMEA Live Attenuated Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Live Attenuated Vaccine for these regions, from 2012 to 2022 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Live Attenuated Vaccine market competition by top manufacturers/players, with Live Attenuated Vaccine sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including

• Astellas Pharma (Japan)
• CSL Limited (Australia)
• Emergent BioSolutions (U.S.)
• GlaxoSmithKline (U.K.)
• Johnson & Johnson (U.S.)
• MedImmune (U.S.)
• Merck & Co (U.S.)
• Pfizer (U.S.)
• Sanofi Pasteur (France)
• Serum Institute of India Pvt (India)

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

• By End User
• Pediatrics
• Adults
• By Disease Indication
• Pneumococcal
• Influenza
• HPV
• Hepatitis
• Rotavirus
• DTP
• Polio
• MMR

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Hospital
• Medical Center
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) Live Attenuated Vaccine Market Report 2017

1 LIVE ATTENUATED VACCINE OVERVIEW

1.1 Product Overview and Scope of Live Attenuated Vaccine
1.2 Classification of Live Attenuated Vaccine
  1.2.1 EMEA Live Attenuated Vaccine Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA Live Attenuated Vaccine Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 Pediatrics
  1.2.4 Adults
1.3 EMEA Live Attenuated Vaccine Market by Application/End Users
  1.3.1 EMEA Live Attenuated Vaccine Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 Hospital
  1.3.3 Medical Center
  1.3.4 Others
1.4 EMEA Live Attenuated Vaccine Market by Region
  1.4.1 EMEA Live Attenuated Vaccine Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Live Attenuated Vaccine (2012-2022)
  1.5.1 EMEA Live Attenuated Vaccine Sales and Growth Rate (2012-2022)
  1.5.2 EMEA Live Attenuated Vaccine Revenue and Growth Rate (2012-2022)

2 EMEA LIVE ATTENUATED VACCINE COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Live Attenuated Vaccine Market Competition by Players/Manufacturers
  2.1.1 EMEA Live Attenuated Vaccine Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA Live Attenuated Vaccine Revenue and Share by Players (2012-2017)
  2.1.3 EMEA Live Attenuated Vaccine Sale Price by Players (2012-2017)
2.2 EMEA Live Attenuated Vaccine (Volume and Value) by Type/Product Category
  2.2.1 EMEA Live Attenuated Vaccine Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA Live Attenuated Vaccine Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA Live Attenuated Vaccine Sale Price by Type (2012-2017)
2.3 EMEA Live Attenuated Vaccine (Volume) by Application
2.4 EMEA Live Attenuated Vaccine (Volume and Value) by Region
  2.4.1 EMEA Live Attenuated Vaccine Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA Live Attenuated Vaccine Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA Live Attenuated Vaccine Sales Price by Region (2012-2017)

3 EUROPE LIVE ATTENUATED VACCINE (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Live Attenuated Vaccine Sales and Value (2012-2017)
  3.1.1 Europe Live Attenuated Vaccine Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe Live Attenuated Vaccine Revenue and Growth Rate (2012-2017)
3.2 Europe Live Attenuated Vaccine Sales and Market Share by Type
3.3 Europe Live Attenuated Vaccine Sales and Market Share by Application
3.4 Europe Live Attenuated Vaccine Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe Live Attenuated Vaccine Sales Volume by Countries (2012-2017)
  3.4.2 Europe Live Attenuated Vaccine Revenue by Countries (2012-2017)
  3.4.3 Germany Live Attenuated Vaccine Sales and Growth Rate (2012-2017)
  3.4.4 France Live Attenuated Vaccine Sales and Growth Rate (2012-2017)
  3.4.5 UK Live Attenuated Vaccine Sales and Growth Rate (2012-2017)
  3.4.6 Russia Live Attenuated Vaccine Sales and Growth Rate (2012-2017)
  3.4.7 Italy Live Attenuated Vaccine Sales and Growth Rate (2012-2017)
  3.4.8 Benelux Live Attenuated Vaccine Sales and Growth Rate (2012-2017)

4 MIDDLE EAST LIVE ATTENUATED VACCINE (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Live Attenuated Vaccine Sales and Value (2012-2017)
  4.1.1 Middle East Live Attenuated Vaccine Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East Live Attenuated Vaccine Revenue and Growth Rate (2012-2017)
4.2 Middle East Live Attenuated Vaccine Sales and Market Share by Type
4.3 Middle East Live Attenuated Vaccine Sales and Market Share by Application
4.4 Middle East Live Attenuated Vaccine Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East Live Attenuated Vaccine Sales Volume by Countries (2012-2017)
  4.4.2 Middle East Live Attenuated Vaccine Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia Live Attenuated Vaccine Sales and Growth Rate (2012-2017)
  4.4.4 Israel Live Attenuated Vaccine Sales and Growth Rate (2012-2017)
  4.4.5 UAE Live Attenuated Vaccine Sales and Growth Rate (2012-2017)
  4.4.6 Iran Live Attenuated Vaccine Sales and Growth Rate (2012-2017)

5 AFRICA LIVE ATTENUATED VACCINE (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Live Attenuated Vaccine Sales and Value (2012-2017)
  5.1.1 Africa Live Attenuated Vaccine Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa Live Attenuated Vaccine Revenue and Growth Rate (2012-2017)
5.2 Africa Live Attenuated Vaccine Sales and Market Share by Type
5.3 Africa Live Attenuated Vaccine Sales and Market Share by Application
5.4 Africa Live Attenuated Vaccine Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa Live Attenuated Vaccine Sales Volume by Countries (2012-2017)
  5.4.2 Africa Live Attenuated Vaccine Revenue by Countries (2012-2017)
  5.4.3 South Africa Live Attenuated Vaccine Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria Live Attenuated Vaccine Sales and Growth Rate (2012-2017)
  5.4.5 Egypt Live Attenuated Vaccine Sales and Growth Rate (2012-2017)
  5.4.6 Algeria Live Attenuated Vaccine Sales and Growth Rate (2012-2017)

6 EMEA LIVE ATTENUATED VACCINE MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 Astellas Pharma (Japan)
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Live Attenuated Vaccine Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Astellas Pharma (Japan) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 CSL Limited (Australia)
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Live Attenuated Vaccine Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 CSL Limited (Australia) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Emergent BioSolutions (U.S.)
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Live Attenuated Vaccine Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Emergent BioSolutions (U.S.) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 GlaxoSmithKline (U.K.)
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Live Attenuated Vaccine Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 GlaxoSmithKline (U.K.) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Johnson & Johnson (U.S.)
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Live Attenuated Vaccine Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Johnson & Johnson (U.S.) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 MedImmune (U.S.)
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Live Attenuated Vaccine Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 MedImmune (U.S.) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Merck & Co (U.S.)
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Live Attenuated Vaccine Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Merck & Co (U.S.) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Pfizer (U.S.)
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 Live Attenuated Vaccine Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Pfizer (U.S.) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Sanofi Pasteur (France)
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Live Attenuated Vaccine Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Sanofi Pasteur (France) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Serum Institute of India Pvt (India)
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 Live Attenuated Vaccine Product Type, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Serum Institute of India Pvt (India) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview

7 LIVE ATTENUATED VACCINE MANUFACTURING COST ANALYSIS

7.1 Live Attenuated Vaccine Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Live Attenuated Vaccine

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Live Attenuated Vaccine Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Live Attenuated Vaccine Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA LIVE ATTENUATED VACCINE MARKET FORECAST (2017-2022)

11.1 EMEA Live Attenuated Vaccine Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA Live Attenuated Vaccine Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA Live Attenuated Vaccine Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA Live Attenuated Vaccine Price and Trend Forecast (2017-2022)
11.2 EMEA Live Attenuated Vaccine Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Live Attenuated Vaccine Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Live Attenuated Vaccine Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Live Attenuated Vaccine Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Live Attenuated Vaccine Sales Forecast by Type (2017-2022)
11.7 EMEA Live Attenuated Vaccine Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Live Attenuated Vaccine
Figure EMEA Live Attenuated Vaccine Sales Volume (K Pcs) by Type (2012-2022)
Figure EMEA Live Attenuated Vaccine Sales Volume Market Share by Type (Product Category) in 2016
Figure Pediatrics Product Picture
Figure Adults Product Picture
Figure EMEA Live Attenuated Vaccine Sales Volume (K Pcs) by Application (2012-2022)
Figure EMEA Sales Market Share of Live Attenuated Vaccine by Application in 2016
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Medical Center Examples
Table Key Downstream Customer in Medical Center
Figure Others Examples
Table Key Downstream Customer in Others
Figure EMEA Live Attenuated Vaccine Market Size (Million USD) by Region (2012-2022)
Figure Europe Live Attenuated Vaccine Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Live Attenuated Vaccine Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Live Attenuated Vaccine Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Live Attenuated Vaccine Revenue (Million USD) Status and Forecast by Countries
Figure Africa Live Attenuated Vaccine Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Live Attenuated Vaccine Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Live Attenuated Vaccine Sales Volume and Growth Rate (2012-2022)
Figure EMEA Live Attenuated Vaccine Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Live Attenuated Vaccine Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table EMEA Live Attenuated Vaccine Sales Volume (K Pcs) of Major Players (2012-2017)
Table EMEA Live Attenuated Vaccine Sales Share by Players (2012-2017)
Figure 2016 Live Attenuated Vaccine Sales Share by Players
Figure 2017 Live Attenuated Vaccine Sales Share by Players
Figure EMEA Live Attenuated Vaccine Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Live Attenuated Vaccine Revenue (Million USD) by Players (2012-2017)
Table EMEA Live Attenuated Vaccine Revenue Share by Players (2012-2017)
Table 2016 EMEA Live Attenuated Vaccine Revenue Share by Players
Table 2017 EMEA Live Attenuated Vaccine Revenue Share by Players
Table EMEA Live Attenuated Vaccine Sale Price (USD/Pcs) by Players (2012-2017)
Table EMEA Live Attenuated Vaccine Sales (K Pcs) and Market Share by Type (2012-2017)
Table EMEA Live Attenuated Vaccine Sales Share by Type (2012-2017)
Figure Sales Market Share of Live Attenuated Vaccine by Type (2012-2017)
Figure EMEA Live Attenuated Vaccine Sales Market Share by Type (2012-2017)
Table EMEA Live Attenuated Vaccine Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Live Attenuated Vaccine Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Live Attenuated Vaccine by Type in 2016
Table EMEA Live Attenuated Vaccine Sale Price (USD/Pcs) by Type (2012-2017)
Table EMEA Live Attenuated Vaccine Sales (K Pcs) and Market Share by Application (2012-2017)
Table EMEA Live Attenuated Vaccine Sales Share by Application (2012-2017)
Figure Sales Market Share of Live Attenuated Vaccine by Application (2012-2017)
Figure EMEA Live Attenuated Vaccine Sales Market Share by Application in 2016
Table EMEA Live Attenuated Vaccine Sales (K Pcs) and Market Share by Region (2012-2017)
Table EMEA Live Attenuated Vaccine Sales Share by Region (2012-2017)
Figure Sales Market Share of Live Attenuated Vaccine by Region (2012-2017)
Figure EMEA Live Attenuated Vaccine Sales Market Share in 2016
Table EMEA Live Attenuated Vaccine Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Live Attenuated Vaccine Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Live Attenuated Vaccine by Region (2012-2017)
Figure EMEA Live Attenuated Vaccine Revenue Market Share Regions in 2016
Table EMEA Live Attenuated Vaccine Sales Price (USD/Pcs) by Region (2012-2017)
Figure Europe Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure Europe Live Attenuated Vaccine Revenue and Growth Rate (2012-2017)
Table Europe Live Attenuated Vaccine Sales (K Pcs) by Type (2012-2017)
Table Europe Live Attenuated Vaccine Market Share by Type (2012-2017)
Figure Europe Live Attenuated Vaccine Market Share by Type in 2016
Table Europe Live Attenuated Vaccine Sales (K Pcs) by Application (2012-2017)
Table Europe Live Attenuated Vaccine Market Share by Application (2012-2017)
Figure Europe Live Attenuated Vaccine Market Share by Application in 2016
Table Europe Live Attenuated Vaccine Sales (K Pcs) by Countries (2012-2017)
Table Europe Live Attenuated Vaccine Sales Market Share by Countries (2012-2017)
Figure Europe Live Attenuated Vaccine Sales Market Share by Countries (2012-2017)
Figure Europe Live Attenuated Vaccine Sales Market Share by Countries in 2016
Table Europe Live Attenuated Vaccine Revenue (Million USD) by Countries (2012-2017)
Table Europe Live Attenuated Vaccine Revenue Market Share by Countries (2012-2017)
Figure Europe Live Attenuated Vaccine Revenue Market Share by Countries (2012-2017)
Figure Europe Live Attenuated Vaccine Revenue Market Share by Countries in 2016
Figure Germany Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure France Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure UK Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure Russia Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure Italy Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure Benelux Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure Middle East Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure Middle East Live Attenuated Vaccine Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Live Attenuated Vaccine Sales (K Pcs) by Type (2012-2017)
Table Middle East Live Attenuated Vaccine Market Share by Type (2012-2017)
Figure Middle East Live Attenuated Vaccine Market Share by Type (2012-2017)
Table Middle East Live Attenuated Vaccine Sales (K Pcs) by Applications (2012-2017)
Table Middle East Live Attenuated Vaccine Market Share by Applications (2012-2017)
Figure Middle East Live Attenuated Vaccine Sales Market Share by Application in 2016
Table Middle East Live Attenuated Vaccine Sales Volume (K Pcs) by Countries (2012-2017)
Table Middle East Live Attenuated Vaccine Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Live Attenuated Vaccine Sales Volume Market Share by Countries in 2016
Table Middle East Live Attenuated Vaccine Revenue (Million USD) by Countries (2012-2017)
Table Middle East Live Attenuated Vaccine Revenue Market Share by Countries (2012-2017)
Figure Middle East Live Attenuated Vaccine Revenue Market Share by Countries (2012-2017)
Figure Middle East Live Attenuated Vaccine Revenue Market Share by Countries in 2016
Figure Saudi Arabia Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure Israel Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure UAE Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure Iran Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure Africa Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure Africa Live Attenuated Vaccine Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Live Attenuated Vaccine Sales (K Pcs) by Type (2012-2017)
Table Africa Live Attenuated Vaccine Sales Market Share by Type (2012-2017)
Figure Africa Live Attenuated Vaccine Sales Market Share by Type (2012-2017)
Figure Africa Live Attenuated Vaccine Sales Market Share by Type in 2016
Table Africa Live Attenuated Vaccine Sales (K Pcs) by Application (2012-2017)
Table Africa Live Attenuated Vaccine Sales Market Share by Application (2012-2017)
Figure Africa Live Attenuated Vaccine Sales Market Share by Application (2012-2017)
Table Africa Live Attenuated Vaccine Sales Volume (K Pcs) by Countries (2012-2017)
Table Africa Live Attenuated Vaccine Sales Market Share by Countries (2012-2017)
Figure Africa Live Attenuated Vaccine Sales Market Share by Countries (2012-2017)
Figure Africa Live Attenuated Vaccine Sales Market Share by Countries in 2016
Table Africa Live Attenuated Vaccine Revenue (Million USD) by Countries (2012-2017)
Table Africa Live Attenuated Vaccine Revenue Market Share by Countries (2012-2017)
Figure Africa Live Attenuated Vaccine Revenue Market Share by Countries (2012-2017)
Figure Africa Live Attenuated Vaccine Revenue Market Share by Countries in 2016
Figure South Africa Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure Nigeria Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure Egypt Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure Algeria Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Table Astellas Pharma (Japan) Live Attenuated Vaccine Basic Information List
Table Astellas Pharma (Japan) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Astellas Pharma (Japan) Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure Astellas Pharma (Japan) Live Attenuated Vaccine Sales Market Share in EMEA (2012-2017)
Figure Astellas Pharma (Japan) Live Attenuated Vaccine Revenue Market Share in EMEA (2012-2017)
Table CSL Limited (Australia) Live Attenuated Vaccine Basic Information List
Table CSL Limited (Australia) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure CSL Limited (Australia) Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure CSL Limited (Australia) Live Attenuated Vaccine Sales Market Share in EMEA (2012-2017)
Figure CSL Limited (Australia) Live Attenuated Vaccine Revenue Market Share in EMEA (2012-2017)
Table Emergent BioSolutions (U.S.) Live Attenuated Vaccine Basic Information List
Table Emergent BioSolutions (U.S.) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Emergent BioSolutions (U.S.) Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure Emergent BioSolutions (U.S.) Live Attenuated Vaccine Sales Market Share in EMEA (2012-2017)
Figure Emergent BioSolutions (U.S.) Live Attenuated Vaccine Revenue Market Share in EMEA (2012-2017)
Table GlaxoSmithKline (U.K.) Live Attenuated Vaccine Basic Information List
Table GlaxoSmithKline (U.K.) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure GlaxoSmithKline (U.K.) Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure GlaxoSmithKline (U.K.) Live Attenuated Vaccine Sales Market Share in EMEA (2012-2017)
Figure GlaxoSmithKline (U.K.) Live Attenuated Vaccine Revenue Market Share in EMEA (2012-2017)
Table Johnson & Johnson (U.S.) Live Attenuated Vaccine Basic Information List
Table Johnson & Johnson (U.S.) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Johnson & Johnson (U.S.) Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure Johnson & Johnson (U.S.) Live Attenuated Vaccine Sales Market Share in EMEA (2012-2017)
Figure Johnson & Johnson (U.S.) Live Attenuated Vaccine Revenue Market Share in EMEA (2012-2017)
Table MedImmune (U.S.) Live Attenuated Vaccine Basic Information List
Table MedImmune (U.S.) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure MedImmune (U.S.) Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure MedImmune (U.S.) Live Attenuated Vaccine Sales Market Share in EMEA (2012-2017)
Figure MedImmune (U.S.) Live Attenuated Vaccine Revenue Market Share in EMEA (2012-2017)
Table Merck & Co (U.S.) Live Attenuated Vaccine Basic Information List
Table Merck & Co (U.S.) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Merck & Co (U.S.) Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure Merck & Co (U.S.) Live Attenuated Vaccine Sales Market Share in EMEA (2012-2017)
Figure Merck & Co (U.S.) Live Attenuated Vaccine Revenue Market Share in EMEA (2012-2017)
Table Pfizer (U.S.) Live Attenuated Vaccine Basic Information List
Table Pfizer (U.S.) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Pfizer (U.S.) Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure Pfizer (U.S.) Live Attenuated Vaccine Sales Market Share in EMEA (2012-2017)
Figure Pfizer (U.S.) Live Attenuated Vaccine Revenue Market Share in EMEA (2012-2017)
Table Sanofi Pasteur (France) Live Attenuated Vaccine Basic Information List
Table Sanofi Pasteur (France) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Sanofi Pasteur (France) Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure Sanofi Pasteur (France) Live Attenuated Vaccine Sales Market Share in EMEA (2012-2017)
Figure Sanofi Pasteur (France) Live Attenuated Vaccine Revenue Market Share in EMEA (2012-2017)
Table Serum Institute of India Pvt (India) Live Attenuated Vaccine Basic Information List
Table Serum Institute of India Pvt (India) Live Attenuated Vaccine Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Serum Institute of India Pvt (India) Live Attenuated Vaccine Sales (K Pcs) and Growth Rate (2012-2017)
Figure Serum Institute of India Pvt (India) Live Attenuated Vaccine Sales Market Share in EMEA (2012-2017)
Figure Serum Institute of India Pvt (India) Live Attenuated Vaccine Revenue Market Share in EMEA (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Live Attenuated Vaccine
Figure Manufacturing Process Analysis of Live Attenuated Vaccine
Figure Live Attenuated Vaccine Industrial Chain Analysis
Table Raw Materials Sources of Live Attenuated Vaccine Major Manufacturers in 2016
Table Major Buyers of Live Attenuated Vaccine
Table Distributors/Traders List
Figure EMEA Live Attenuated Vaccine Sales (K Pcs) and Growth Rate Forecast (2017-2022)
Figure EMEA Live Attenuated Vaccine Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Live Attenuated Vaccine Price (USD/Pcs) and Trend Forecast (2017-2022)
Table EMEA Live Attenuated Vaccine Sales (K Pcs) Forecast by Region (2017-2022)
Figure EMEA Live Attenuated Vaccine Sales Market Share Forecast by Region (2017-2022)
Table EMEA Live Attenuated Vaccine Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Live Attenuated Vaccine Revenue Market Share Forecast by Region (2017-2022)
Table Europe Live Attenuated Vaccine Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Europe Live Attenuated Vaccine Sales Market Share Forecast by Countries (2017-2022)
Table Europe Live Attenuated Vaccine Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Live Attenuated Vaccine Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Live Attenuated Vaccine Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Middle East Live Attenuated Vaccine Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Live Attenuated Vaccine Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Live Attenuated Vaccine Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Live Attenuated Vaccine Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Africa Live Attenuated Vaccine Sales Market Share Forecast by Countries (2017-2022)
Table Africa Live Attenuated Vaccine Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Live Attenuated Vaccine Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Live Attenuated Vaccine Sales (K Pcs) Forecast by Type (2017-2022)
Figure EMEA Live Attenuated Vaccine Sales Market Share Forecast by Type (2017-2022)
Table EMEA Live Attenuated Vaccine Sales (K Pcs) Forecast by Application (2017-2022)
Figure EMEA Live Attenuated Vaccine Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources